The FDA has approved Keytruda in combination with pemetrexed and platinum chemotherapy, as first-line Tx of unresectable advanced or metastatic malignant pleural mesothelioma.

Keytruda plus chemo has been approved for unresectable advanced or metastatic malignant pleural mesothelioma based on ...

Committee for Medicinal Products for Human Use (CHMP) has recommended approval of MSD’s KEYTRUDA for two gynaecological ...

Drug major Merck & Co., Inc. (MRK) announced Wednesday that the U.S. Food and Drug Administration has approved its anti-PD-1 therapy ...

The FDA has approved Merck's Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for first-line ...

Study findings were mixed regarding the postsurgical combination of Keytruda and chemotherapy with or without radiation among ...

Merck & Co Inc.'s (MRK) anti-PD-1 therapy, KEYTRUDA (pembrolizumab), when combined with chemotherapy before surgery and continued as ...

The regulatory body has now approved Keytruda in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult patients with unresectable advanced or metastatic ...

The combination statistically significantly improved overall survival, reducing the risk of death by 21% compared with chemotherapy alone. The Food and Drug Administration (FDA) has approved ...

227/KEYNOTE-483 trial, in which KEYTRUDA plus chemotherapy demonstrated a statistically significant improvement in overall survival versus chemotherapy alone. The company noted that KEYTRUDA plus ...